5. Eylea

Regeneron's Eylea is hoping to beat out highly touted challenger Beovu from Novartis. (Regeneron)

Companies: Regeneron, Bayer
2019 sales: $7.99 billion
Projected 2026 sales: $6.68 billion
Projected CAGR: -3%
Used for: wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, macular edema

Regeneron and Bayer's bestselling eye drug Eylea has taken the wet age-related macular degeneration market by storm in recent years. But a serious challenger in Novartis' Beovu is hoping to chip away at Eylea's lead. 

Eylea posted $7.99 billion in sales in 2019 and could see a slight 3% decline in sales through 2026 as Beovu siphons off market share, Evaluate Pharma reported. That would leave Regeneron and Bayer's med with $6.68 billion in sales that year. 

It might have been worse. Beovu presented an existential challenge of sorts for Eylea when it was approved in October, but a safety warning for the drug may hinder Novartis' ability to give the older med a run for its money. 

RELATED: 'Lightning struck': How a safety alert shifted doctor sentiment on Novartis' Beovu

5. Eylea

Suggested Articles

The next wave of immuno-oncology R&D includes drugs that interact with a wide range of emerging immune targets, including TIGIT and CD47.

Emerging targets like KRAS, MET and RET are inspiring novel kinase inhibitor development and fueling billions in pharma deals.

Despite the rise of cell therapies to treat cancer, R&D centered on novel tyrosine kinase inhibitors and immuno-oncology targets is booming.